Neuroscientist Karyn Frick, a professor of psychological and brain sciences at the University of Wisconsin-Milwaukee, is leading research into how estrogens regulate memory, aiming to create new treatments for age-related memory loss and dementia. By studying sex-based differences in neurobiology, Frick’s work seeks to address why middle-aged females often experience more significant memory decline than … Read more
Researchers have identified the protein Arc as a critical vehicle that transports toxic Tau protein between neurons, potentially driving the progression of Alzheimer’s disease. According to a study published in Cell by investigators at University of Utah Health and Washington University in St. Louis, interrupting this intercellular transport mechanism could offer a new therapeutic strategy … Read more
Eli Lilly and Company is acquiring biotech firm AtaiBeckley for an up-front payment of $2.8 billion to integrate the psychedelic drug candidate BPL-003 into its neuroscience portfolio. According to company terms, Lilly will pay $6.75 per outstanding share, with potential milestone payments reaching an additional $1 billion ($2.50 per share), according to the deal terms. … Read more
Individuals with early-onset dementia—defined as a diagnosis occurring before age 65—experience a significant, accelerating decline in work productivity up to 15 years before receiving a clinical diagnosis. Research published in the journal Neurology on July 8, 2026, reveals that these patients face an average productivity loss of 74,577 Euros (approximately $86,000 USD) compared to their … Read more
New research from Texas A&M Health indicates that cognitive flexibility—the brain’s ability to adapt to changing rules and unexpected situations—may decline months before traditional memory loss symptoms appear in Alzheimer’s disease. Published in Nature Communications, the study suggests that identifying these executive function deficits could provide a critical window for earlier clinical intervention. Executive Function … Read more
Researchers at the DZNE (German Center for Neurodegenerative Diseases) have discovered that neurons autonomously dictate their own structure through an internal genetic protocol, rather than relying on external chemical signals. By using a protein complex called Arp2/3 to rhythmically remodel their internal cytoskeleton, young nerve cells “zip” and “unzip” their structure to select a single … Read more
Researchers at the Netherlands Institute for Neuroscience have identified a link between myelin sheath degradation and abnormal brain activity during sleep, potentially providing a new non-invasive biomarker for neurodegenerative diseases. According to research presented at the Federation of European Neuroscience Societies (FENS) Forum 2026, myelin damage triggers epilepsy-like electrical spikes and disrupts critical oscillations exclusively … Read more
Digital Biomarkers and the Future of Longitudinal Brain Health Researchers at the UCSF Neuroscape research center and Samsung are launching the Technology for Aging Health – Digital Approaches (TAH-DA) study, a longitudinal effort to identify biometric predictors of cognitive decline. By pairing Samsung’s Galaxy Watch and Galaxy Tab A9 with Neuroscape’s proprietary software, the study … Read more
New research published in Science Translational Medicine indicates that congenital cerebral ventriculomegaly (CCV)—a condition marked by fluid-filled brain ventricle swelling—is frequently linked to rare, damaging gene mutations. According to investigators at the Mass General Brigham Neuroscience Institute, these genetic findings suggest that CCV is often a marker of underlying neurodevelopmental disorders, including autism spectrum disorder, … Read more
Researchers have identified a potential therapeutic pathway for Alzheimer’s disease by targeting DNA damage within brain neurons. A study published in FEBS Open Bio reports that the molecule KCL-286 successfully repairs neuronal DNA in mouse models, simultaneously reducing brain inflammation and abnormal immune activity associated with neurodegeneration. How does KCL-286 target Alzheimer’s disease? The drug … Read more